These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12897767)

  • 1. Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity.
    Fitzgerald CE; Patel SB; Becker JW; Cameron PM; Zaller D; Pikounis VB; O'Keefe SJ; Scapin G
    Nat Struct Biol; 2003 Sep; 10(9):764-9. PubMed ID: 12897767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis of inhibitor selectivity in MAP kinases.
    Wang Z; Canagarajah BJ; Boehm JC; Kassisà S; Cobb MH; Young PR; Abdel-Meguid S; Adams JL; Goldsmith EJ
    Structure; 1998 Sep; 6(9):1117-28. PubMed ID: 9753691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase.
    Fox T; Coll JT; Xie X; Ford PJ; Germann UA; Porter MD; Pazhanisamy S; Fleming MA; Galullo V; Su MS; Wilson KP
    Protein Sci; 1998 Nov; 7(11):2249-55. PubMed ID: 9827991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substituting c-Jun N-terminal kinase-3 (JNK3) ATP-binding site amino acid residues with their p38 counterparts affects binding of JNK- and p38-selective inhibitors.
    Fricker M; Lograsso P; Ellis S; Wilkie N; Hunt P; Pollack SJ
    Arch Biochem Biophys; 2005 Jun; 438(2):195-205. PubMed ID: 15907786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles.
    Kumar S; McDonnell PC; Gum RJ; Hand AT; Lee JC; Young PR
    Biochem Biophys Res Commun; 1997 Jun; 235(3):533-8. PubMed ID: 9207191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and characterization of a substrate selective p38alpha inhibitor.
    Davidson W; Frego L; Peet GW; Kroe RR; Labadia ME; Lukas SM; Snow RJ; Jakes S; Grygon CA; Pargellis C; Werneburg BG
    Biochemistry; 2004 Sep; 43(37):11658-71. PubMed ID: 15362850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular basis for p38 protein kinase inhibitor specificity.
    Lisnock J; Tebben A; Frantz B; O'Neill EA; Croft G; O'Keefe SJ; Li B; Hacker C; de Laszlo S; Smith A; Libby B; Liverton N; Hermes J; LoGrasso P
    Biochemistry; 1998 Nov; 37(47):16573-81. PubMed ID: 9843424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p38 MAP kinase inhibitors. Part 3: SAR on 3,4-dihydropyrimido[4,5-d]pyrimidin-2-ones and 3,4-dihydropyrido[4,3-d]pyrimidin-2-ones.
    Natarajan SR; Wisnoski DD; Thompson JE; O'Neill EA; O'Keefe SJ
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4400-4. PubMed ID: 16750629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benzimidazolone p38 inhibitors.
    Dombroski MA; Letavic MA; McClure KF; Barberia JT; Carty TJ; Cortina SR; Csiki C; Dipesa AJ; Elliott NC; Gabel CA; Jordan CK; Labasi JM; Martin WH; Peese KM; Stock IA; Svensson L; Sweeney FJ; Yu CH
    Bioorg Med Chem Lett; 2004 Feb; 14(4):919-23. PubMed ID: 15012994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha.
    Ge B; Gram H; Di Padova F; Huang B; New L; Ulevitch RJ; Luo Y; Han J
    Science; 2002 Feb; 295(5558):1291-4. PubMed ID: 11847341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active mutants of the human p38alpha mitogen-activated protein kinase.
    Diskin R; Askari N; Capone R; Engelberg D; Livnah O
    J Biol Chem; 2004 Nov; 279(45):47040-9. PubMed ID: 15284239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catalysis and function of the p38 alpha.MK2a signaling complex.
    Lukas SM; Kroe RR; Wildeson J; Peet GW; Frego L; Davidson W; Ingraham RH; Pargellis CA; Labadia ME; Werneburg BG
    Biochemistry; 2004 Aug; 43(31):9950-60. PubMed ID: 15287722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.
    Colletti SL; Frie JL; Dixon EC; Singh SB; Choi BK; Scapin G; Fitzgerald CE; Kumar S; Nichols EA; O'Keefe SJ; O'Neill EA; Porter G; Samuel K; Schmatz DM; Schwartz CD; Shoop WL; Thompson CM; Thompson JE; Wang R; Woods A; Zaller DM; Doherty JB
    J Med Chem; 2003 Jan; 46(3):349-52. PubMed ID: 12540232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the distal C162S mutation on the energetics of drug binding to p38alpha MAP kinase.
    Todorova NA; Doseeva V; Ramprakash J; Schwarz FP
    Arch Biochem Biophys; 2008 Jan; 469(2):232-42. PubMed ID: 17996717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P38 MAP kinase inhibitors: evolution of imidazole-based and pyrido-pyrimidin-2-one lead classes.
    Natarajan SR; Doherty JB
    Curr Top Med Chem; 2005; 5(10):987-1003. PubMed ID: 16178742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804.
    Xing L; Shieh HS; Selness SR; Devraj RV; Walker JK; Devadas B; Hope HR; Compton RP; Schindler JF; Hirsch JL; Benson AG; Kurumbail RG; Stegeman RA; Williams JM; Broadus RM; Walden Z; Monahan JB
    Biochemistry; 2009 Jul; 48(27):6402-11. PubMed ID: 19496616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.
    Trejo A; Arzeno H; Browner M; Chanda S; Cheng S; Comer DD; Dalrymple SA; Dunten P; Lafargue J; Lovejoy B; Freire-Moar J; Lim J; Mcintosh J; Miller J; Papp E; Reuter D; Roberts R; Sanpablo F; Saunders J; Song K; Villasenor A; Warren SD; Welch M; Weller P; Whiteley PE; Zeng L; Goldstein DM
    J Med Chem; 2003 Oct; 46(22):4702-13. PubMed ID: 14561090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. X-ray structure of p38α bound to TAK-715: comparison with three classic inhibitors.
    Azevedo R; van Zeeland M; Raaijmakers H; Kazemier B; de Vlieg J; Oubrie A
    Acta Crystallogr D Biol Crystallogr; 2012 Aug; 68(Pt 8):1041-50. PubMed ID: 22868770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p38 MAPK signaling during murine preimplantation development.
    Natale DR; Paliga AJ; Beier F; D'Souza SJ; Watson AJ
    Dev Biol; 2004 Apr; 268(1):76-88. PubMed ID: 15031106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel 3D-QSAR comparative molecular field analysis (CoMFA) model of imidazole and quinazolinone functionalized p38 MAP kinase inhibitors.
    Sperandio da Silva GM; Sant'Anna CM; Barreiro EJ
    Bioorg Med Chem; 2004 Jun; 12(12):3159-66. PubMed ID: 15158784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.